Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of 3 doses of
Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and
extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of
moderate intensity.